Celsion Corporation (NASDAQ: CLN)

Celsion Corporation (NASDAQ: CLN) is committed to developing and commercializing oncology drugs including tumor-targeting treatments. The company has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Hospital-Albert Einstein Medical School. By using technology that delivers high concentrations of anti-cancer agents directly the tumor site, they are able to maximize efficacy while minimizing side-effects common to cancer treatment. For further information, visit the Company’s web site at www.celsion.com.